{"id":"acetazolamide-based-medical-therapy","safety":{"commonSideEffects":[{"rate":"10-50%","effect":"Paresthesia (tingling in extremities)"},{"rate":"10-30%","effect":"Altered taste (dysgeusia)"},{"rate":"5-15%","effect":"Hypokalemia (low potassium)"},{"rate":"5-10%","effect":"Metabolic acidosis"},{"rate":"1-5%","effect":"Nephrolithiasis (kidney stones)"},{"rate":"5-15%","effect":"Fatigue"}]},"_chembl":null,"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"Acetazolamide is a carbonic anhydrase inhibitor that decreases the production of aqueous humor in the eye and cerebrospinal fluid in the central nervous system by blocking the enzyme carbonic anhydrase. This leads to reduced intraocular pressure and intracranial pressure, making it useful in conditions where pressure reduction is therapeutic. The drug also has mild diuretic properties due to inhibition of renal carbonic anhydrase.","oneSentence":"Acetazolamide inhibits carbonic anhydrase to reduce aqueous humor production and cerebrospinal fluid formation, thereby lowering intraocular and intracranial pressure.","_ai_confidence":"high"},"_scrapedAt":"2026-03-28T00:44:05.130Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Glaucoma and ocular hypertension"},{"name":"Idiopathic intracranial hypertension"},{"name":"High altitude cerebral edema"}]},"trialDetails":[{"nctId":"NCT07469722","phase":"PHASE2, PHASE3","title":"POcus INTERvention for Tailoring Diuretic Strategy in Acute Decompensated Heart Failure","status":"NOT_YET_RECRUITING","sponsor":"Hospital de Clinicas de Porto Alegre","startDate":"2026-03-23","conditions":"Acute Heart Failure (AHF), Congestive Heart Failure Acute, Diuretic Effect","enrollment":128},{"nctId":"NCT05707442","phase":"PHASE3","title":"Stent Implantation Versus Medical Therapy for Idiopathic IntracraniaL Hypertension (SIMPLE)","status":"RECRUITING","sponsor":"Beijing Tiantan Hospital","startDate":"2023-02-16","conditions":"Idiopathic Intracranial Hypotension, Venous Sinus Stenosis","enrollment":74}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":0,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"phase_3","status":"active","brandName":"Acetazolamide-based medical therapy","genericName":"Acetazolamide-based medical therapy","companyName":"Beijing Tiantan Hospital","companyId":"beijing-tiantan-hospital","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Acetazolamide is a small molecule that inhibits carbonic anhydrase 1, a validated mechanism of action according to ChEMBL. It is being studied in clinical trials, including those for Acute Heart Failure (AHF), Congestive Heart Failure Acute, Diuretic Effect, Lung Ultrasonography Score, Ultrasonography, and Doppler, alongside other diuretics such as Furosemide and Hydrochlorothiazide.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}